USPTO serial 99672754
IBES
Reviewed by CopyMark Law Group
Status 681
- Filing date
- Status date
- Registration date
- —
- Examiner
- WHELAN, JAIME M
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with IBES?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Joe McKinney Muncy
Joe McKinney Muncy Muncy, Geissler, Olds & Lowe, P.C.125 S. Royal StreetAlexandria, VA 22314United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Syringes filled with pharmaceuticals for the treatment of osteoarthritis and other degenerative joint diseases; Syringes filled with pharmaceuticals for chronic wound healing, including non-healing ulcers; Syringes filled with immune-modulating pharmaceuticals for autoimmune diseases and transplant rejection prevention; Syringes filled with pharmaceuticals for cardiovascular diseases, including acute myocardial infarction and ischemic conditions; Syringes filled with regenerative pharmaceuticals for skin and tissue repair; Organotherapy preparations; Biological preparations for use in cell cultures for medical purposes; Pharmaceutical and biological preparations for diagnostic, medical, therapeutic and prophylactic use, namely for the treatment of genetic, autoimmune and inflammatory diseases, disorders and deficiencies, and for preventing organ transplant rejection; Pharmaceutical preparations for use in treatment, amelioration and prophylaxis of diseases, disorders and suppression of the immune system; Pharmaceutical preparations for cell therapy for medical purposes; Pharmaceutical preparations for gene therapy for medical purposes; Pharmaceutical preparations for genetically modifying human and animal cells for diagnostic and medical purposes; Pharmaceutical preparations for therapies to modulate the immune system; Pharmaceutical preparations for therapeutic delivery of nucleic acids; Medical pharmaceutical preparations containing viral vectors for therapeutic and prophylactic purposes for the treatment of genetic, autoimmune and inflammatory diseases, disorders and deficiencies, and for preventing organ transplant rejection; Medical preparations containing nucleic acid vectors for therapeutic and prophylactic purposes for the treatment of genetic, autoimmune and inflammatory diseases, disorders and deficiencies, and for preventing organ transplant rejection; Stem cells for medical purposes; Biological reagent for medical purposes; Opotherapy preparations | ACTIVE | — |
| 040 | Custom manufacturing of pharmaceuticals, excluding services relating to the development or establishment of general bioprocesses or biomanufacturing facilities for the life sciences industry; Custom biomanufacturing of pharmaceuticals, excluding services relating to the development or establishment of general bioprocesses or biomanufacturing facilities for the life sciences industry | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Oct 28, 2026 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Oct 1, 2026 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Sep 30, 2026 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Sep 30, 2026 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Sep 30, 2026 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jul 2, 2026 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jul 2, 2026 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jul 2, 2026 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 15, 2026 | DOCK | ASSIGNED TO EXAMINER | — |
| Feb 28, 2026 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Feb 26, 2026 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Feb 26, 2026 | NWAP | NEW APPLICATION ENTERED | — |